最新一期业绩显示，2025年一季报，公司实现营业收入3.32亿元，同比-7.23%；净利润1.30亿元，同 比-29.66%，销售毛利率69.61%。 上海微创心脉医疗科技(集团)股份有限公司的主营业务是主动脉及外周血管介入医疗器械的研发、生产 和销售。公司的主要产品是胸主动脉覆膜支架系统、腹主动脉覆膜支架系统、术中支架类、球囊类、支 架类。公司获评上海市政府质量金奖、科创板公司价值30强、首届"未来20·中国A股上市公司成长力年 度企业"；子公司鸿脉、蓝脉、拓脉获评"科技型中小企业"，蓝脉首次通过高新技术企业认定并获评"张 江年度新锐"企业；Castor分支型胸主动脉覆膜支架进入国家知识产权局《第二十五届中国专利金奖预 获奖项目》公示名录;静脉支架等入选《上海市"新优药械"产品目录》和《浦东新区创新药械产品推荐 目录》，另有5个项目获评浦东职工科技创新项目。总裁朱清入选"明珠领军人才"，刘梦钦、王金耀、 屠春霖、樊亚明入选"明珠工程师"。 7月11日，心脉医疗今日收盘95.92元，上涨1.30%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到26.42倍，创67天以来新低，总市值118.23亿 ...

最新一期业绩显示，2025年一季报，公司实现营业收入3.32亿元，同比-7.23%；净利润1.30亿元，同 比-29.66%，销售毛利率69.61%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13心脉医疗26.0423.213.03116.53亿行业平均 51.2949.024.57106.75亿行业中值37.0237.322.4950.63亿1九安医疗10.2410.360.81172.88亿2英科医疗 10.3411.150.92163.38亿3新华医疗14.3913.331.1792.22亿4奥美医疗15.2314.931.5755.03亿5山东药玻 15.4315.481.77145.93亿6振德医疗15.5514.660.9956.46亿7康德莱15.6915.701.3033.81亿8维力医疗 16.3917.031.9237.37亿9奥泰生物16.5017.401.3352.63亿10九强生物16.5615.402.0382.01亿11安杰思 18.2118.422.2054.05亿12安图生物18.7617.912.41213.94亿 来源：金融界 7月2日，心脉医疗今日收盘94 ...

序号股票简称PE(TTM)PE(静)市净率总市值(元)52心脉医疗24.2421.602.82108.47亿行业平均 49.6447.924.61106.85亿行业中值36.3637.152.4549.28亿1天益医疗-1776.29-3042.591.9022.64亿2澳华内 镜-644.66323.335.1667.94亿3诺唯赞-407.58-482.062.2487.22亿4爱朋医疗-359.62273.204.3329.51亿5博晖 创新-330.17523.933.5248.44亿6奥精医疗-139.08-203.851.8325.81亿7硕世生物-137.56-2010.081.2340.24亿 8睿昂基因-102.37-84.041.4513.25亿9康泰医学-89.13-75.303.1858.66亿10中红医疗-72.45-57.790.9250.35亿 11华大智造-55.85-49.563.85297.77亿 股东方面，截至2025年3月31日，心脉医疗股东户数18176户，较上次增加523户，户均持股市值35.28万 元，户均持股数量2.76万股。 上海微创心脉医疗科技(集团)股份有 ...

报名：首届 全球医美科技大会 | 奖项评选 报名： 第二届全球医疗科技大会 | 奖项评选 合作伙伴征集：2025全球手术机器人大会 2025年5月15日，国家药品监督管理局批准了 先健科技（深圳）有限公司 （简称"先健科技"）的 " 主动脉弓支架系统 "（国械注准20253130950 ）创新产品注 册申请。 该产品包括主动脉弓主体支架系统和主动脉弓分支支架系统，与同公司主动脉覆膜支架破膜系统配合使用，适用于治疗需要 重建左锁骨下动脉血运的Stanford B型 夹层患者 。 截至目前，我国上市的创新医疗器械累计 352 项。 | 索引号 | XZXK-2025-211 | 主题分类 | | --- | --- | --- | | 标题 | 主动脉弓支架系统获批上市 | | | 发布日期 | 2025-05-15 | | # 产品研发背景 主动脉腔内介入治疗 近年来受到临床医生的高度认可，已进入高速发展时期。累及升主动脉及主动脉弓部的病变占全部主动脉夹层病变的 70% 左右，但由于人体 主动脉弓部血管解剖形态复杂并负责颅内供血，一直以来是主动脉疾病腔内治疗的难点，尤其是 弓上3个分支动脉的重建 ，通常面临较大 ...

Core Insights - The company reported a revenue of 2.066 billion yuan for 2024, representing a year-over-year increase of 25.18%, with a net profit of 673 million yuan, up 26.08% [1] - The company’s Q4 2024 revenue was 541 million yuan, a 23.93% increase year-over-year, while Q1 2025 revenue reached 564 million yuan, also reflecting a 23.93% growth [1] Group 1: Business Performance - The electrophysiology business showed steady growth with revenue of 440 million yuan in 2024, a 19.73% increase, and a gross margin of 73.76% [2] - The coronary pathway revenue was 1.054 billion yuan, up 33.3%, with a gross margin of 73.21%, while peripheral intervention revenue reached 351 million yuan, a 37.09% increase [2] - The overall gross margin for the company improved to 72.31%, an increase of 1.04 percentage points, driven by enhanced production efficiency and scale effects [2] Group 2: Market Expansion - Domestic market revenue reached 1.769 billion yuan, a 25.68% increase, with over 200 new hospital admissions in electrophysiology and more than 15,000 three-dimensional surgeries completed [3] - International market revenue was 280 million yuan, a 19.62% increase, with the company’s own brand growing over 45%, particularly in the Middle East, Africa, and Europe [3] - The company made significant progress in product registration and channel development in the CIS region, enhancing its product matrix in PCI and achieving breakthroughs in high-end hospitals in Spain, France, Italy, and Germany [3] Group 3: Research and Development - The company invested 290 million yuan in R&D in 2024, accounting for 14% of its revenue, to strengthen its capabilities in interventional devices [3] - New product launches included pulse ablation catheters and various vascular intervention products, contributing to a robust pipeline for long-term growth [3] Group 4: Profit Forecast - Revenue projections for 2025-2027 are 2.695 billion, 3.398 billion, and 4.279 billion yuan, with year-over-year growth rates of 30.47%, 26.08%, and 25.93% respectively [4] - Expected net profits for the same period are 907 million, 1.156 billion, and 1.453 billion yuan, with growth rates of 34.74%, 27.49%, and 25.68% respectively [4]